Vertical Pathway Targeting in Cancer Therapy

Advances in Pharmacology

Volumn 65, Issue , 2012, Pages 1-26

  Shahbazian, David ^a   Sznol, Joshua ^a   Kluger, Harriet M ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Cancer; Oncogenic signaling; Small molecule inhibitors

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL)IMIDAZO[5,1 F][1,2,4]TRIAZIN 7 YL)CYCLOHEXANECARBOXYLIC ACID; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AZD 2014; AZD 8055; BEVACIZUMAB; BUPARLISIB; CETUXIMAB; DABRAFENIB; DASATINIB; ERLOTINIB; FORETINIB; GEFITINIB; IMATINIB; INK 128; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NILOTINIB; PERIFOSINE; PICTRELISIB; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RAPAMYCIN DERIVATIVE; RILOTUMUMAB; SELUMETINIB; SORAFENIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB;

ADVANCED CANCER; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER THERAPY; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LIGAND BINDING; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MANTLE CELL LYMPHOMA; MELANOMA; METASTASIS; NEUROENDOCRINE TUMOR; OVARY CANCER; PANCREAS TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SOLID TUMOR; THYROID CANCER;

EID: 84865846073     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-397927-8.00001-4     Document Type: Chapter

References (112)

1. Amini A., Moghaddam S.M., Morris D.L., Pourgholami M.H. The critical role of vascular endothelial growth factor in tumor angiogenesis. Current Cancer Drug Targets 2012.
2. Argiris A., Cohen E., Karrison T., Esparaz B., Mauer A., Ansari R., et al. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biology and Therapy 2006, 5(7):766-770.
3. Aziz S.A., Jilaveanu L.B., Zito C., Camp R.L., Rimm D.L., Conrad P., et al. Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clinical Cancer Research 2010, 16(24):6029-6039.
4. Beltran P.J., Chung Y.A., Moody G., Mitchell P., Cajulis E., Vonderfecht S., et al. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models. Journal of Pharmacology and Experimental Therapeutics 2011, 337(3):644-654.
5. Bendell J.C., Rodon J., Burris H.A., de Jonge M., Verweij J., Birle D., et al. Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology 2012, 30(3):282-290.
6. Benjamin D., Colombi M., Moroni C., Hall M.N. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nature Reviews Drug Discovery 2011, 10(11):868-880.
7. Bhagwat S.V., Gokhale P.C., Crew A.P., Cooke A., Yao Y., Mantis C., et al. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Molecular Cancer Therapeutics 2011, 10(8):1394-1406.
8. Bollag G., Hirth P., Tsai J., Zhang J., Ibrahim P.N., Cho H., et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467(7315):596-599.
9. Breen E.C. VEGF in biological control. Journal of Cellular Biochemistry 2007, 102(6):1358-1367.
10. Brevet M., Shimizu S., Bott M.J., Shukla N., Zhou Q., Olshen A.B., et al. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy. Journal of Thoracic Oncology 2011, 6(5):864-874.
11. Bukowski R.M. Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab. Cancer Management and Research 2010, 2:83-96.
12. Burger R.A., Brady M.F., Bookman M.A., Fleming G.F., Monk B.J., Huang H., et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. New England Journal of Medicine 2011, 365(26):2473-2483.
13. Cao P., Maira S.M., Garcia-Echeverria C., Hedley D.W. Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. British Journal of Cancer 2009, 100(8):1267-1276.
14. Carpenter E.L., Haglund E.A., Mace E.M., Deng D., Martinez D., Wood A.C., et al. Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma. Oncogene 2012.
15. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. Journal of Clinical Investigation 2008, 118(9):3065-3074.
16. Chandarlapaty S., Sawai A., Scaltriti M., Rodrik-Outmezguine V., Grbovic-Huezo O., Serra V., et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011, 19(1):58-71.
17. Chen K.F., Chen H.L., Tai W.T., Feng W.C., Hsu C.H., Chen P.J., et al. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. Journal of Pharmacology and Experimental Therapeutics 2011, 337(1):155-161.
18. Chiarini F., Fala F., Tazzari P.L., Ricci F., Astolfi A., Pession A., et al. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Research 2009, 69(8):3520-3528.
19. Choo A.Y., Yoon S.O., Kim S.G., Roux P.P., Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type--specific repression of mRNA translation. Proceedings of the National Academy of Sciences U S A 2008, 105(45):17414-17419.
20. Crowder R.J., Phommaly C., Tao Y., Hoog J., Luo J., Perou C.M., et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor--positive breast cancer. Cancer Research 2009, 69(9):3955-3962.
21. Crowell J.A., Steele V.E., Fay J.R. Targeting the AKT protein kinase for cancer chemoprevention. Molecular Cancer Therapeutics 2007, 6(8):2139-2148.
22. Duntas L.H., Bernardini R. Sorafenib: rays of hope in thyroid cancer. Thyroid 2010, 20(12):1351-1358.
23. Edwards J., Krishna N.S., Witton C.J., Bartlett J.M. Gene amplifications associated with the development of hormone-resistant prostate cancer. Clinical Cancer Research 2003, 9(14):5271-5281.
24. Eichhorn P.J., Gili M., Scaltriti M., Serra V., Guzman M., Nijkamp W., et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Research 2008, 68(22):9221-9230.
25. Eisen T., Ahmad T., Flaherty K.T., Gore M., Kaye S., Marais R., et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. British Journal of Cancer 2006, 95(5):581-586.
26. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316(5827):1039-1043.
27. Erba H.P., Pham D.C., Zaiden R., Vu H., Tai S. Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib. Clinical Advances in Hematology and Oncology 2011, 9(10):734-745.
28. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. New England Journal of Medicine 2007, 356(2):125-134.
29. Fedorenko I.V., Paraiso K.H., Smalley K.S. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochemical Pharmacology 2011, 82(3):201-209.
30. Fiszman G.L., Jasnis M.A. Molecular mechanisms of trastuzumab resistance in HER2 overexpressing breast cancer. International Journal of Breast Cancer 2011, 352182.
31. Garcia-Martinez J.M., Alessi D.R. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochemical Journal 2008, 416(3):375-385.
32. Gatius S., Velasco A., Azueta A., Santacana M., Pallares J., Valls J., et al. FGFR2 alterations in endometrial carcinoma. Modern Pathology 2011, 24(11):1500-1510.
33. Gupta R., Maitland M.L. Sunitinib, hypertension, and heart failure: a model for kinase inhibitor-mediated cardiotoxicity. Current Hypertension Report 2011, 13(6):430-435.
34. Hahn W.C., Weinberg R.A. Rules for making human tumor cells. New England Journal of Medicine 2002, 347(20):1593-1603.
35. Hatzivassiliou G., Song K., Yen I., Brandhuber B.J., Anderson D.J., Alvarado R., et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464(7287):431-435.
36. Heidorn S.J., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140(2):209-221.
37. Holmes D. PI3K pathway inhibitors approach junction. Nature Reviews Drug Discovery 2011, 10(8):563-564.
38. Hong S., Han S.B. Overcoming metastatic melanoma with BRAF inhibitors. Archives of Pharmacal Research 2011, 34(5):699-701.
39. Huang X., Gao L., Wang S., McManaman J.L., Thor A.D., Yang X., et al. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Research 2010, 70(3):1204-1214.
40. Hubbard S.R., Miller W.T. Receptor tyrosine kinases: mechanisms of activation and signaling. Current Opinion in Cell Biology 2007, 19(2):117-123.
41. Ikenoue T., Inoki K., Yang Q., Zhou X., Guan K.L. Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J 2008, 27(14):1919-1931.
42. Jaiswal B.S., Janakiraman V., Kljavin N.M., Eastham-Anderson J., Cupp J.E., Liang Y., et al. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PLoS One 2009, 4(5):e5717.
43. Janku F., Lee J.J., Tsimberidou A.M., Hong D.S., Naing A., Falchook G.S., et al. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One 2011, 6(7):e22769.
44. Janne P.A., Gray N., Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nature Reviews Drug Discovery 2009, 8(9):709-723.
45. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer Journal for Clinicians 2011, 61(2):69-90.
46. Johannessen C.M., Boehm J.S., Kim S.Y., Thomas S.R., Wardwell L., Johnson L.A., et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468(7326):968-972.
47. Kane R.C., Farrell A.T., Madabushi R., Booth B., Chattopadhyay S., Sridhara R., et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 2009, 14(1):95-100.
48. Knowling M., Blackstein M., Tozer R., Bramwell V., Dancey J., Dore N., et al. A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: a National Cancer Institute of Canada Clinical Trials Group trial. Investigational New Drugs 2006, 24(5):435-439.
49. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non--small-cell lung cancer. New England Journal of Medicine 2010, 363(18):1693-1703.
50. Lamarca A., Feliu J., Barriuso J. Severe toxicity caused by sorafenib in hepatocellular carcinoma match the data from renal cell carcinoma. British Journal of Cancer 2012.
51. Liu L., Shi H., Liu Y., Anderson A., Peterson J., Greger J., et al. Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells. Molecular Cancer Therapeutics 2011, 10(3):518-530.
52. Liu P., Cheng H., Santiago S., Raeder M., Zhang F., Isabella A., et al. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nature Medicine 2011, 17(9):1116-1120.
53. Liu R., Liu D., Xing M. The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAFV600E inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells. Journal of Clinical Endocrinology and Metabolism 2011.
54. Liu T.J., Koul D., LaFortune T., Tiao N., Shen R.J., Maira S.M., et al. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Molecular Cancer Therapeutics 2009, 8(8):2204-2210.
55. Maira S.M., Pecchi S., Huang A., Burger M., Knapp M., Sterker D., et al. Identification and characterization of NVP-BKM120, an orally available pan class I PI3-Kinase inhibitor. Molecular Cancer Therapeutics 2011.
56. Matsumoto K., Arao T., Hamaguchi T., Shimada Y., Kato K., Oda I., et al. FGFR2 gene amplification and clinicopathological features in gastric cancer. British Journal of Cancer 2012, 106(4):727-732.
57. Maurer G., Tarkowski B., Baccarini M. Raf kinases in cancer - roles and therapeutic opportunities. Oncogene 2011, 30(32):3477-3488.
58. McCormack P.L., Keam S.J. Spotlight on dasatinib in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemiadagger. BioDrugs 2012, 26(1):61-64.
59. McCubrey J.A., Steelman L.S., Abrams S.L., Chappell W.H., Russo S., Ove R., et al. Emerging MEK inhibitors. Expert Opinion on Emerging Drugs 2010, 15(2):203-223.
60. McLellan B., Kerr H. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. Dermatology and Therapy 2011, 24(4):396-400.
61. Mendoza M.C., Er E.E., Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends in Biochemical Sciences 2011, 36(6):320-328.
62. Merkel O., Hamacher F., Sifft E., Kenner L., Greil R. Novel therapeutic options in anaplastic large cell lymphoma: molecular targets and immunological tools. Molecular Cancer Therapeutics 2011, 10(7):1127-1136.
63. Nazarian R., Shi H., Wang Q., Kong X., Koya R.C., Lee H., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468(7326):973-977.
64. Nikolaou V.A., Stratigos A.J., Flaherty K.T., Tsao H. Melanoma: new insights and new therapies. Journal of Investigative Dermatology 2012.
65. O'Brien C., Wallin J.J., Sampath D., GuhaThakurta D., Savage H., Punnoose E.A., et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clinical Cancer Research 2010, 16(14):3670-3683.
66. Pal S.K., Reckamp K., Yu H., Figlin R.A. Akt inhibitors in clinical development for the treatment of cancer. Expert Opinion on Investigational Drugs 2010, 19(11):1355-1366.
67. Panka D.J., Cho D.C., Atkins M.B., Mier J.W. GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. Journal of Biological Chemistry 2008, 283(2):726-732.
68. Paraiso K.H., Xiang Y., Rebecca V.W., Abel E.V., Chen Y.A., Munko A.C., et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Research 2011, 71(7):2750-2760.
69. Perren T.J., Swart A.M., Pfisterer J., Ledermann J.A., Pujade-Lauraine E., Kristensen G., et al. A phase 3 trial of bevacizumab in ovarian cancer. New England Journal of Medicine 2011, 365(26):2484-2496.
70. Petroulakis E., Mamane Y., Le Bacquer O., Shahbazian D., Sonenberg N. mTOR signaling: implications for cancer and anticancer therapy. British Journal of Cancer 2006, 94(2):195-199.
71. Planchard D. Bevacizumab in non--small-cell lung cancer: a review. Expert Review of Anticancer Therapy 2011, 11(8):1163-1179.
72. Pohlmann P.R., Mayer I.A., Mernaugh R. Resistance to Trastuzumab in breast cancer. Clinical Cancer Research 2009, 15(24):7479-7491.
73. Poulikakos P.I., Rosen N. Mutant BRAF melanomas-dependence and resistance. Cancer Cell 2011, 19(1):11-15.
74. Poulikakos P.I., Solit D.B. Resistance to MEK inhibitors: should we co-target upstream?. Science Signaling 2011, 4(166):pe16.
75. Quek R., Wang Q., Morgan J.A., Shapiro G.I., Butrynski J.E., Ramaiya N., et al. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clinical Cancer Research 2011, 17(4):871-879.
76. Rajakulendran T., Sahmi M., Lefrancois M., Sicheri F., Therrien M. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 2009, 461(7263):542-545.
77. Raynaud F.I., Eccles S.A., Patel S., Alix S., Box G., Chuckowree I., et al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Molecular Cancer Therapeutics 2009, 8(7):1725-1738.
78. Richards C.J., Je Y., Schutz F.A., Heng D.Y., Dallabrida S.M., Moslehi J.J., et al. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. Journal of Clinical Oncology 2011, 29(25):3450-3456.
79. Rosenzweig S.A. Acquired resistance to drugs targeting receptor tyrosine kinases. Biochemical Pharmacology 2011.
80. Salk J.J., Fox E.J., Loeb L.A. Mutational heterogeneity in human cancers: origin and consequences. Annual Review of Pathology 2010, 5:51-75.
81. Salphati L., Pang J., Plise E.G., Chou B., Halladay J.S., Olivero A.G., et al. Preclinical pharmacokinetics of the novel PI3K inhibitor GDC-0941 and prediction of its pharmacokinetics and efficacy in human. Xenobiotica 2011, 41(12):1088-1099.
82. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307(5712):1098-1101.
83. Schoffski P., Garcia J.A., Stadler W.M., Gil T., Jonasch E., Tagawa S.T., et al. A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. British Journal of Urology International 2011, 108(5):679-686.
84. Schubbert S., Shannon K., Bollag G. Hyperactive Ras in developmental disorders and cancer. Nature Reviews Cancer 2007, 7(4):295-308.
85. Sell C., Rubini M., Rubin R., Liu J.P., Efstratiadis A., Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proceedings of the National Academy of Sciences U S A 1993, 90(23):11217-11221.
86. Sequist L.V., von Pawel J., Garmey E.G., Akerley W.L., Brugger W., Ferrari D., et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. Journal of Clinical Oncology 2011, 29(24):3307-3315.
87. Serra V., Markman B., Scaltriti M., Eichhorn P.J., Valero V., Guzman M., et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Research 2008, 68(19):8022-8030.
88. Sharma S.V., Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes and Development 2007, 21(24):3214-3231.
89. Shimizu T., Tolcher A.W., Papadopoulos K.P., Beeram M., Rasco D., Smith L.S., et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clinical Cancer Research 2012.
90. Sierra J.R., Tsao M.S. c-MET as a potential therapeutic target and biomarker in cancer. Therapeutic Advances in Medical Oncology 2011, 3(Suppl. 1):S21-35.
91. Simon R., Richter J., Wagner U., Fijan A., Bruderer J., Schmid U., et al. High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Research 2001, 61(11):4514-4519.
92. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine 2001, 344(11):783-792.
93. Sordella R., Bell D.W., Haber D.A., Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305(5687):1163-1167.
94. Stommel J.M., Kimmelman A.C., Ying H., Nabioullin R., Ponugoti A.H., Wiedemeyer R., et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007, 318(5848):287-290.
95. Su K.Y., Chen H.Y., Li K.C., Kuo M.L., Yang J.C., Chan W.K., et al. Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. Journal of Clinical Oncology 2012, 30(4):433-440.
96. Takahashi O., Komaki R., Smith P.D., Jurgensmeier J.M., Ryan A.J., Bekele B.N., et al. Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. Clinical Cancer Research 2012.
97. Takeuchi H., Kondo Y., Fujiwara K., Kanzawa T., Aoki H., Mills G.B., et al. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Research 2005, 65(8):3336-3346.
98. Takeuchi K., Ito F. Receptor tyrosine kinases and targeted cancer therapeutics. Biological and Pharmaceutical Bulletin 2011, 34(12):1774-1780.
99. Treins C., Warne P.H., Magnuson M.A., Pende M., Downward J. Rictor is a novel target of p70 S6 kinase-1. Oncogene 2010, 29(7):1003-1016.
100. Um S.H., Frigerio F., Watanabe M., Picard F., Joaquin M., Sticker M., et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004, 431(7005):200-205.
101. Villanueva J., Vultur A., Lee J.T., Somasundaram R., Fukunaga-Kalabis M., Cipolla A.K., et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by co-targeting MEK and IGF-1R/PI3K. Cancer Cell 2010, 18(6):683-695.
102. Waldner M.J., Neurath M.F. Targeting the VEGF signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets 2012.
103. Weigelt B., Warne P.H., Downward J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 2011, 30(29):3222-3233.
104. Weinstein I.B. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 2002, 297(5578):63-64.
105. Wen P.Y., Schiff D., Cloughesy T.F., Raizer J.J., Laterra J., Smitt M., et al. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncology 2011, 13(4):437-446.
106. Wheeler D.L., Huang S., Kruser T.J., Nechrebecki M.M., Armstrong E.A., Benavente S., et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008, 27(28):3944-3956.
107. Whittaker S., Kirk R., Hayward R., Zambon A., Viros A., Cantarino N., et al. Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Science Translational Medicine 2010, 2(35). 35ra41.
108. Xu A.M., Huang P.H. Receptor tyrosine kinase coactivation networks in cancer. Cancer Research 2010, 70(10):3857-3860.
109. Xu C.X., Li Y., Yue P., Owonikoko T.K., Ramalingam S.S., Khuri F.R., et al. The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo. PLoS One 2011, 6(6):e20899.
110. Yao J.C., Shah M.H., Ito T., Bohas C.L., Wolin E.M., Van Cutsem E., et al. Everolimus for advanced pancreatic neuroendocrine tumors. New England Journal of Medicine 2011, 364(6):514-523.
111. Yuan T.L., Cantley L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27(41):5497-5510.
112. Zhu X., Stergiopoulos K., Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncologica 2009, 48(1):9-17.